Melperone

Summary

Melperone (CHEMBL1531134) is a phase-3 clinical-stage small molecule (ATC N05AD03); indicated across 5 conditions including psychotic disorder and anxiety.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N05AD03
• Indications: 5 conditions
• Clinical trials: 2
• Chemistry: 263.35 Da · C16H22FNO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1531134
Name	Melperone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	15387
ATC	N05AD03
Molecular formula	C16H22FNO
Molecular weight	263.35
InChIKey	DKMFBWQBDIGMHM-UHFFFAOYSA-N

SMILES: CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F

IUPAC name: 1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one

Also known as: Bunil, FG 5111, FG-5111, Melperona, Melperone, Metylperon, SID50112880, MELPERONE, SID144206136, SID170466288, melperone, MMV1725886

Parent form; salt/anhydrous children: CHEMBL4551527

Patent coverage: 937 distinct patent families (3,728 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Menin/Histone-lysine N-methyltransferase MLL, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Histamine H3 receptor.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	6.52	AC50	305	nM	CHEMBL_ACT_25195069
ADRA1A	6.52	AC50	299.8	nM	CHEMBL_ACT_25219336
DRD1	6.48	AC50	334.5	nM	CHEMBL_ACT_25115773
ADRA2A	6	AC50	1002	nM	CHEMBL_ACT_25156992
HTR1A	5.57	AC50	2688	nM	CHEMBL_ACT_25165587
KCNH2	5.31	AC50	4850	nM	CHEMBL_ACT_25118753

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	3	MONDO:0005485	EFO:0005407
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT00125138	PHASE2	COMPLETED	Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).